Bristol Myers Squibb reported that the company was abandoning the BCMA CAR-T therapy orva-cel and taking a $470 million write-off.
Can Janssen Cure Cancer? Company’s 80+ ASH Presentations Suggest It’s On Right Track
American Society of Hematology (ASH) Annual Meeting, B-cell maturation antigen (BCMA), Cancer, Clinical Data, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Hematology, Janssen, Johnson & Johnson, R&D, Relapse/Refractory Multiple Myeloma, T-Cells, TherapeuticsThe Janssen Pharmaceutical Companies of Johnson & Johnson has a presence in more than 80 of the hematology studies presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition in December.
Bristol Myers Squibb and bluebird bio are eying a potential quick approval for a CAR-T treatment for multiple myeloma after the U.S. Food and Drug Administration accepted the Biologics License Application under priority review for idecabtagene vicleucel.
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
GSK’s blood cancer drug wins European panel thumbs-up
Antibody-Drug Conjugates (ADCs), B-cell maturation antigen (BCMA), Blockbusters, Blood Cancers, Cells, Chemotherapy, European Medicines Agency, FDA/Regulatory, Immunomodulatory Agents, Recommended For Approval, Relapse/Refractory Multiple MyelomaA panel of the European Medicines Agency recommended approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, days after a similar nod from a U.S. Food and Drug Administration panel.
An independent panel to the U.S. Food and Drug Administration voted in favor of approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks.
FDA Declines Review of Bristol Myers Squibb and bluebird’s Multiple Myeloma Therapy
B-cell maturation antigen (BCMA), Biologics License Application (BLA), Business, CAR-T Therapy, Collaborations, FDA, FDA/Regulatory, Immunotherapies, Investors, Refusal to File letter, Relapse/Refractory Multiple Myeloma, Shareholders, SharesShares of bluebird bio were down in trading after the U.S. Food and Drug Administration declined to review a Biologics License Application for the experimental CAR-T treatment idecabtagene vicleucel for multiple myeloma co-developed with Bristol Myers Squibb.
GlaxoSmithKline submitted a Biologics License Application to the U.S. FDA based upon results from the pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.
GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.
AbbVie Inc., along with Teneobio Inc. and that company’s affiliate TeneoOne Inc., announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.